Solid Biosciences (SLDB)
(Delayed Data from NSDQ)
$6.82 USD
-0.01 (-0.15%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $6.82 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SLDB 6.82 -0.01(-0.15%)
Will SLDB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SLDB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLDB
Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade
SLDB Stock Rallies 60% in a Month: Here's What You Should Know
SLDB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
Other News for SLDB
Solid Biosciences (SLDB) Awards Restricted Stock Units to New Employees
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SLDB Stock News
Solid Biosciences reports inducement grants under Nasdaq listing rule
Solid Biosciences (SLDB) Advances Gene Therapy with FDA Fast Track
Solid Biosciences gets FDA fast track status for heart disease therapy